|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
According to the local government health agency (Secretarla de Salud, SSA in Spanish), from 1994 to 2017 a reduction in the incidence of hepatitis related to HAV has been reported.
|
31113583 |
2020 |
|
Hepatitis A
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the local government health agency (Secretarla de Salud, SSA in Spanish), from 1994 to 2017 a reduction in the incidence of hepatitis related to HAV has been reported.
|
31113583 |
2020 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
SSc patients with OAB were characterized by old age, a long history of morbidity (15.4 vs. 11.2 years, p < .01), high anti-centromere antibody positive rate (75.9 vs. 44%, p < .05), high incidence of gastroesophageal reflux disease (93.1 vs. 73.3%, p < .05), low anti-SS-A antibody positive rate (6.9 vs. 26.8%, p < .05), and low incidence of internal lung disease (17.9 vs. 45.7%, p < .05) compared to SSc patients without OAB.
|
30836050 |
2020 |
|
Sexually Transmitted Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
To examine knowledge of menstruation, HIV and STIs other than HIV across eight sites in SSA to develop effective programmatic interventions enabling adolescents to achieve positive SRH as their transition to adulthood.
|
31691455 |
2020 |
|
Thickening of pleura
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared with CTD-ILD patients, IPAF patients were more likely to present initially with respiratory symptoms, with higher rates of fever, cough and expectoration, dyspnea, and Velcro crackles; anti-Ro52 titers were higher; incidences of honeycombing opacity, reticulate opacity, patchy opacity, and pleural thickening were greater.
|
31758424 |
2020 |
|
Chronic graft-versus-host disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver cGVHD was significantly associated with anti-Ro52-positivity.
|
31489804 |
2020 |
|
Overactive Bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
SSc patients with OAB were characterized by old age, a long history of morbidity (15.4 vs. 11.2 years, p < .01), high anti-centromere antibody positive rate (75.9 vs. 44%, p < .05), high incidence of gastroesophageal reflux disease (93.1 vs. 73.3%, p < .05), low anti-SS-A antibody positive rate (6.9 vs. 26.8%, p < .05), and low incidence of internal lung disease (17.9 vs. 45.7%, p < .05) compared to SSc patients without OAB.
|
30836050 |
2020 |
|
Anemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By multivariate analyses, xerophthalmia, histological positivity for lower salivary gland biopsy (LSGB), anti-SSA/Ro52-positive, reduced complement 3 (C3) levels, hypoalbuminemia and anemia retained significant association with renal involvement in pSS (all P < 0.05).
|
30411528 |
2019 |
|
Anemia, Hemolytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
JSLE patients with fine-coarse speckled pattern and anti-RNP, anti-Sm, anti-Ro-52 or anti-SSA developed leukopenia, thrombocytopenia and renal involvement, whilst hemolytic anemia and serositis were commonly found in those with anti-Ro-52.
|
31012595 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data support that nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling.
|
30719818 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data support that nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling.
|
30719818 |
2019 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.
|
31127862 |
2019 |
|
Deglutition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The incidence of mortality, subcutaneous emphysema, hoarseness and dysphagia in patients who were positive for both anti-MDA5 and anti-Ro52 antibodies was significantly higher than in patients positive for only anti-MDA5 antibodies.
|
30767866 |
2019 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Further studies are warranted to explore interventions that could attenuate the risk of stroke attributable to renal disease among patients with hypertension in SSA.
|
30471633 |
2019 |
|
Kidney Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Further studies are warranted to explore interventions that could attenuate the risk of stroke attributable to renal disease among patients with hypertension in SSA.
|
30471633 |
2019 |
|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
<i>HCP5</i> rs3099844 was associated with anti-SSA (<i>P</i> = 0.006, OR = 3.07) and anti-SSB (<i>P</i> = 0.005, OR = 2.66) antibodies, severity of focus score (<i>P</i> = 0.03, OR = 12), and lymphoma development (<i>P</i> = 0.002, OR = 7.23).
|
30882006 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<i>SHISA3</i> suppressed NPC cell invasion and metastasis <i>in vitro</i> and <i>in vivo</i> by impeding the E3 ubiquitin ligase tripartite motif containing 21 (TRIM21)-mediated ubiquitination and degradation small G protein signaling modulator 1 (SGSM1) and by inhibiting the MAPK pathway activation.
|
30573520 |
2019 |
|
Pericarditis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glomerulonephritis and pericarditis occurred in 25% and 40% of anti-U1-RNP-positive patients, respectively, but rarely in the other groups; these features occurred only in those with coexisting anti-Ro52 autoantibodies.
|
30824556 |
2019 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, inhibition of vascular endothelial inflammation by TRIM21 provides a novel therapeutic target to lessen pulmonary inflammation.
|
31184939 |
2019 |
|
Rheumatic Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4-81.7], <i>p</i> = 0.02) and inflammatory rheumatism (OR 4.6 [1.6-13.8], <i>p</i> = 0.006) in contrast to systemic lupus (OR 0.2 [0.1-0.3], <i>p</i> < 10<sup>-4</sup>) or primary Sjögren's syndrome (OR 0.1 [0.06-0.2], <i>p</i> < 10<sup>-4</sup>).
|
30915082 |
2019 |
|
Sialadenitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Anti-SSA(Ro) antibodies were detected in 48% while seronegative patients were diagnosed with Sjögren's syndrome based on sialadenitis on minor salivary gland biopsy with a focus score ≥1.
|
31354737 |
2019 |
|
Antiphospholipid Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We selected a core of an antiphospholipid syndrome-like SLE (aPL+ group; positive in the lupus anticoagulant (LA) test and negative for all three of SSA (Ro52 and Ro60) and SSB antibodies) and a Sjögren's syndrome-like SLE (SSA/SSB+ group; positive for all three of SSA (Ro52 and Ro60) and SSB antibodies but negative in the LA test).
|
30777133 |
2019 |
|
Polyglandular Type I Autoimmune Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
A few APECED subjects also harbored autoantibodies to Ro52 and La, but only Ro60 autoantibodies were weakly associated with a small subset of APECED patients with sicca.
|
31095438 |
2019 |
|
Lichen Planus, Oral
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Enhanced T-cell proliferation and IL-6 secretion mediated by overexpression of TRIM21 in oral lesions of patients with oral lichen planus.
|
31353628 |
2019 |
|
Inclusion Body Myositis (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tripartite motif containing 21 (TRIM21) was identified as a potentially new IBM autoantigen.
|
31494268 |
2019 |